A liver Hif-2α–Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition (original) (raw)

Nature Medicine volume 19, pages 1331–1337 (2013)Cite this article

Subjects

Abstract

Insulin initiates diverse hepatic metabolic responses, including gluconeogenic suppression and induction of glycogen synthesis and lipogenesis1,2. The liver possesses a rich sinusoidal capillary network with a higher degree of hypoxia and lower gluconeogenesis in the perivenous zone as compared to the rest of the organ3. Here, we show that diverse vascular endothelial growth factor (VEGF) inhibitors improved glucose tolerance in nondiabetic C57BL/6 and diabetic db/db mice, potentiating hepatic insulin signaling with lower gluconeogenic gene expression, higher glycogen storage and suppressed hepatic glucose production. VEGF inhibition induced hepatic hypoxia through sinusoidal vascular regression and sensitized liver insulin signaling through hypoxia-inducible factor-2α (Hif-2α, encoded by Epas1) stabilization. Notably, liver-specific constitutive activation of HIF-2α, but not HIF-1α, was sufficient to augment hepatic insulin signaling through direct and indirect induction of insulin receptor substrate-2 (Irs2), an essential insulin receptor adaptor protein4,5,6. Further, liver Irs2 was both necessary and sufficient to mediate Hif-2α and Vegf inhibition effects on glucose tolerance and hepatic insulin signaling. These results demonstrate an unsuspected intersection between Hif-2α−mediated hypoxic signaling and hepatic insulin action through Irs2 induction, which can be co-opted by Vegf inhibitors to modulate glucose metabolism. These studies also indicate distinct roles in hepatic metabolism for Hif-1α, which promotes glycolysis7,8,9, and Hif-2α, which suppresses gluconeogenesis, and suggest new treatment approaches for type 2 diabetes mellitus.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Leavens, K.F. & Birnbaum, M.J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit. Rev. Biochem. Mol. Biol. 46, 200–215 (2011).
    Article CAS PubMed Google Scholar
  2. Taniguchi, C.M., Emanuelli, B. & Kahn, C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96 (2006).
    Article CAS PubMed Google Scholar
  3. Jungermann, K. Zonation of metabolism and gene expression in liver. Histochem. Cell Biol. 103, 81–91 (1995).
    Article CAS PubMed Google Scholar
  4. Kubota, N. et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 8, 49–64 (2008).
    Article CAS PubMed Google Scholar
  5. Dong, X. et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 116, 101–114 (2006).
    Article CAS PubMed Google Scholar
  6. Dong, X.C. et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65–76 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  7. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α. Cell 140, 280–293 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  8. Hu, C.J. et al. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 α (HIF-1α) and HIF-2α in stem cells. Mol. Cell Biol. 26, 3514–3526 (2006).
    Article CAS PubMed PubMed Central Google Scholar
  9. Rankin, E.B. et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068–1077 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  10. Kaelin, W.G. Jr. & Ratcliffe, P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393–402 (2008).
    Article CAS PubMed Google Scholar
  11. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
    Article CAS PubMed Google Scholar
  12. Alitalo, K. & Carmeliet, P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219–227 (2002).
    Article CAS PubMed Google Scholar
  13. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576 (2006).
    Article CAS PubMed Google Scholar
  14. Billemont, B. et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99, 1380–1382 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  15. Hagberg, C.E. et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490, 426–430 (2012).
    Article CAS PubMed Google Scholar
  16. Kuo, C.J. et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98, 4605–4610 (2001).
    Article CAS PubMed PubMed Central Google Scholar
  17. Tam, B.Y. et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med. 12, 793–800 (2006).
    Article CAS PubMed Google Scholar
  18. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  19. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393–11398 (2002).
    Article CAS PubMed PubMed Central Google Scholar
  20. Liang, W.C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951–961 (2006).
    Article CAS PubMed Google Scholar
  21. Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209–5218 (1999).
    CAS PubMed Google Scholar
  22. Fan, X. et al. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J. 22, 3571–3580 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  23. Mancuso, M.R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).
    Article CAS PubMed PubMed Central Google Scholar
  24. Canettieri, G. et al. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab. 2, 331–338 (2005).
    Article CAS PubMed Google Scholar
  25. Ide, T. et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351–357 (2004).
    Article CAS PubMed Google Scholar
  26. Shimomura, I. et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77–86 (2000).
    Article CAS PubMed Google Scholar
  27. Lecomte, V. et al. A new role for sterol regulatory element binding protein 1 transcription factors in the regulation of muscle mass and muscle cell differentiation. Mol. Cell Biol. 30, 1182–1198 (2010).
    Article CAS PubMed Google Scholar
  28. Yeo, E.J., Cho, Y.S., Kim, M.S. & Park, J.W. Contribution of HIF-1α or HIF-2α to erythropoietin expression: in vivo evidence based on chromatin immunoprecipitation. Ann. Hematol. 87, 11–17 (2008).
    Article CAS PubMed Google Scholar
  29. Covello, K.L. et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557–570 (2006).
    Article CAS PubMed PubMed Central Google Scholar
  30. Mastrogiannaki, M. et al. HIF-2α, but not HIF-1α, promotes iron absorption in mice. J. Clin. Invest. 119, 1159–1166 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  31. Shah, Y.M., Matsubara, T., Ito, S., Yim, S.H. & Gonzalez, F.J. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab. 9, 152–164 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  32. Rankin, E.B. et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell Biol. 29, 4527–4538 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  33. Wang, X.L. et al. Ablation of ARNT/HIF1β in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones. Cell Metab. 9, 428–439 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  34. Scully, M.S. et al. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp. Diabetes Res. 2011, 910159 (2011).
    Article PubMed PubMed Central CAS Google Scholar
  35. Meng, R., Zhu, D., Bi, Y., Yang, D. & Wang, Y. Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice. PLoS ONE 8, e53557 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  36. Mardilovich, K. & Shaw, L.M. Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. Cancer Res. 69, 8894–8901 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  37. Taniguchi, C.M. et al. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat. Med. doi:10.1038/nm.3294.
    Article CAS PubMed PubMed Central Google Scholar
  38. Qu, A. et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 54, 472–483 (2011).
    Article CAS PubMed Google Scholar
  39. Bracken, C.P. et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1α and HIF-2α stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281, 22575–22585 (2006).
    Article CAS PubMed Google Scholar
  40. Gruber, M. et al. Acute postnatal ablation of Hif-2α results in anemia. Proc. Natl. Acad. Sci. USA 104, 2301–2306 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  41. Postic, C. et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell–specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274, 305–315 (1999).
    Article CAS PubMed Google Scholar
  42. Jacobi, J. et al. Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Gene Ther. 11, 302–309 (2004).
    Article CAS PubMed Google Scholar
  43. Ayala, J.E. et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J. Vis. Exp. 57, 3188 (2011).
    Google Scholar
  44. Steele, R., Wall, J.S., De Bodo, R.C. & Altszuler, N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am. J. Physiol. 187, 15–24 (1956).
    Article CAS PubMed Google Scholar
  45. Mulligan, K.X., Morris, R.T., Otero, Y.F., Wasserman, D.H. & McGuinness, O.P. Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia. PLoS ONE 7, e30160 (2012).
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank R. DePinho, L. Harshman, B. Tam, C. Chartier, D. Suchet and members of the Kuo laboratory for insightful comments and C. Her, J. Kovalski, K. Thabet and D. Nandamundi for technical assistance. We thank G. Fuh (Genentech) for B20.4.1.1 antibody, C. Chartier (Stanford) for the human HIF1A allele lacking the inhibitory ODD (HIF-1αΔODD) and M. Montminy (Salk) for Ad-IRS2. Fellowship support was from the Stanford Medical Scientist Training Program (K.W. and L.M.M.), NIGMS US National Institutes of Health (NIH) GM-07365 training grant (K.W.), Stanford Cardiovascular Institute T32 training grant 1K12HL087746 (S.M.P.), Molecular and Cellular Immunobiology Program training grant 5T32AI07290 (L.M.M.), NIH American Recovery and Reinvestment Act Supplement 1R01HL074267 (L.M.M.), Radiological Society of North America Research Resident grants 1018 and 1111 (C.M.T.), NIH DK084206 (J.P.A.) and Molecular Endocrinology Training Program grant T32DK007563 (K.X.M.). This work was supported by P30 DK026743 (Cell Biology Core Facility, University of California–San Francisco Liver Center) to J.J.M., NIH RO1DK043748, P60 DK020593 and U24DK059637 to O.P.M., NIH CA67166 and the Sydney Frank Foundation to A.J.G. and a Stanford Developmental Cancer Research Award and NIH R01HL074267, R01NS064517 and R01CA158528 to C.J.K.

Author information

Author notes

  1. Kevin Wei, Stephanie M Piecewicz and Lisa M McGinnis: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology, Stanford University School of Medicine, Stanford, California, USA
    Kevin Wei, Stephanie M Piecewicz, Lisa M McGinnis, Carol W-M Chan, David Kuo, Jenny Yuan, Mario Vallon & Calvin J Kuo
  2. Division of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
    Cullen M Taniguchi & Amato J Giaccia
  3. Regeneron Pharmaceuticals, Tarrytown, New York, USA
    Stanley J Wiegand, Keith Anderson, Lori C Morton & Gavin Thurston
  4. Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Kimberly X Mulligan & Owen P McGuinness
  5. INSERM U1060, Institut national de la Recherche Agronomique 1235, Université de Lyon, Lyon, France
    Etienne Lefai
  6. Abramson Family Cancer Research Institute, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    M Celeste Simon
  7. University of California–San Francisco Liver Center, San Francisco General Hospital, San Francisco, California, USA
    Jacquelyn J Maher
  8. INSERM U855, Université de Lyon, Lyon, France
    Gilles Mithieux & Fabienne Rajas
  9. Division of Endocrinology and Metabolism, Stanford University School of Medicine, Stanford, California, USA
    Justin P Annes

Authors

  1. Kevin Wei
    You can also search for this author inPubMed Google Scholar
  2. Stephanie M Piecewicz
    You can also search for this author inPubMed Google Scholar
  3. Lisa M McGinnis
    You can also search for this author inPubMed Google Scholar
  4. Cullen M Taniguchi
    You can also search for this author inPubMed Google Scholar
  5. Stanley J Wiegand
    You can also search for this author inPubMed Google Scholar
  6. Keith Anderson
    You can also search for this author inPubMed Google Scholar
  7. Carol W-M Chan
    You can also search for this author inPubMed Google Scholar
  8. Kimberly X Mulligan
    You can also search for this author inPubMed Google Scholar
  9. David Kuo
    You can also search for this author inPubMed Google Scholar
  10. Jenny Yuan
    You can also search for this author inPubMed Google Scholar
  11. Mario Vallon
    You can also search for this author inPubMed Google Scholar
  12. Lori C Morton
    You can also search for this author inPubMed Google Scholar
  13. Etienne Lefai
    You can also search for this author inPubMed Google Scholar
  14. M Celeste Simon
    You can also search for this author inPubMed Google Scholar
  15. Jacquelyn J Maher
    You can also search for this author inPubMed Google Scholar
  16. Gilles Mithieux
    You can also search for this author inPubMed Google Scholar
  17. Fabienne Rajas
    You can also search for this author inPubMed Google Scholar
  18. Justin P Annes
    You can also search for this author inPubMed Google Scholar
  19. Owen P McGuinness
    You can also search for this author inPubMed Google Scholar
  20. Gavin Thurston
    You can also search for this author inPubMed Google Scholar
  21. Amato J Giaccia
    You can also search for this author inPubMed Google Scholar
  22. Calvin J Kuo
    You can also search for this author inPubMed Google Scholar

Contributions

K.W., S.M.P., L.M.M., C.M.T., S.J.W., K.A., M.V., C.W.-M.C. and K.X.M. designed and performed experiments, D.K. and J.Y. provided technical assistance, L.C.M., E.L., G.M., F.R., J.J.M. and M.C.S. provided reagents, J.P.A., O.P.M., G.T., A.J.G. and C.J.K. designed experiments, K.W., S.M.P., L.M.M., C.M.T., O.P.M. and C.J.K. wrote the manuscript.

Corresponding author

Correspondence toCalvin J Kuo.

Ethics declarations

Competing interests

S.W., K.A., L.M. and G.T. are employees of Regeneron Pharmaceuticals, which manufactures aflibercept.

Supplementary information

Rights and permissions

About this article

Cite this article

Wei, K., Piecewicz, S., McGinnis, L. et al. A liver Hif-2α–Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition.Nat Med 19, 1331–1337 (2013). https://doi.org/10.1038/nm.3295

Download citation